FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
SALT LAKE CITY, Dec. 28, 2016 -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2017 JP Morgan Healthcare Conference at 6:00 p.m. ET on January 9, 2017, at the Westin St. Francis Hotel in San Francisco, California.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, GeneSight, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Media Contact: Ron Rogers (908) 285-0248 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
